These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25987336)

  • 41. Cytokine therapy in metastatic renal cancer.
    Davis ID
    N Engl J Med; 1998 Sep; 339(12):850; author reply 851. PubMed ID: 9750084
    [No Abstract]   [Full Text] [Related]  

  • 42. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 43. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
    Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
    Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon alpha for the treatment of advanced renal cancer.
    Ravaud A; Dilhuydy MS
    Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic therapy for renal cell carcinoma.
    Ko YJ; Atkins MB
    Cancer Chemother Biol Response Modif; 2005; 22():263-72. PubMed ID: 16110616
    [No Abstract]   [Full Text] [Related]  

  • 46. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nephrectomy for metastatic renal-cell cancer.
    Bolger G
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11932483
    [No Abstract]   [Full Text] [Related]  

  • 48. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
    Padrik P
    Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer.
    Parry-Jones N; Gore ME; Taylor J; Treleaven JG
    Clin Lab Haematol; 1999 Dec; 21(6):407-8. PubMed ID: 10671995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nephrectomy for metastatic renal-cell cancer.
    Copur MS; Ledakis P; Norvell M
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
    [No Abstract]   [Full Text] [Related]  

  • 51. Nephrectomy for metastatic renal-cell cancer.
    Polo JL
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936124
    [No Abstract]   [Full Text] [Related]  

  • 52. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy for metastatic renal cell carcinoma.
    Wirth MP
    Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemo-immunotherapy in RCC: the end of a story.
    Escudier B
    Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385
    [No Abstract]   [Full Text] [Related]  

  • 55. Cytokines and cytotoxic agents in renal cell carcinoma: a review.
    Stahl M; Wilke HJ; Seeber S; Schmoll HJ
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):70-9. PubMed ID: 1553577
    [No Abstract]   [Full Text] [Related]  

  • 56. Renal cell carcinoma: a priority malignancy for development and study of novel therapies.
    Motzer RJ
    J Clin Oncol; 2003 Apr; 21(7):1193-4. PubMed ID: 12663704
    [No Abstract]   [Full Text] [Related]  

  • 57. Metastatic RCC arising in a transplant kidney.
    Kunisch-Hoppe M; Hoppe M; Bohle RM; Rauber K; Weimar B; Friemann S; Stahl U; Rau WS
    Eur Radiol; 1998; 8(8):1441-3. PubMed ID: 9853232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
    Atzpodien J; Reitz M
    Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cytokine treatment of renal cell carcinoma].
    Tazaki H
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):29-36. PubMed ID: 8291913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.